HK1254573A1 - 包含苯基氨基嘧啶衍生物的藥物組合物 - Google Patents

包含苯基氨基嘧啶衍生物的藥物組合物

Info

Publication number
HK1254573A1
HK1254573A1 HK18113869.1A HK18113869A HK1254573A1 HK 1254573 A1 HK1254573 A1 HK 1254573A1 HK 18113869 A HK18113869 A HK 18113869A HK 1254573 A1 HK1254573 A1 HK 1254573A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
phenylaminopyrimidine derivative
phenylaminopyrimidine
derivative
pharmaceutical
Prior art date
Application number
HK18113869.1A
Other languages
English (en)
Inventor
Durga Maheswari Parvataneni
Mitrabhanu Mohanty
Venkata Satyanarayana Appadwedula
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of HK1254573A1 publication Critical patent/HK1254573A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK18113869.1A 2015-12-18 2018-10-30 包含苯基氨基嘧啶衍生物的藥物組合物 HK1254573A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN6951CH2015 2015-12-18
PCT/IN2016/050035 WO2017103941A1 (en) 2015-12-18 2016-01-30 Pharmaceutical compositions comprising phenylaminopyrimidine derivative

Publications (1)

Publication Number Publication Date
HK1254573A1 true HK1254573A1 (zh) 2019-07-19

Family

ID=59055898

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113869.1A HK1254573A1 (zh) 2015-12-18 2018-10-30 包含苯基氨基嘧啶衍生物的藥物組合物

Country Status (32)

Country Link
US (1) US10383872B2 (zh)
EP (1) EP3389633B1 (zh)
JP (2) JP6896738B2 (zh)
KR (1) KR20180102584A (zh)
CN (1) CN108495620B (zh)
AU (1) AU2016373574B2 (zh)
BR (1) BR112018012458A2 (zh)
CA (1) CA3008634A1 (zh)
CL (1) CL2018001590A1 (zh)
CO (1) CO2018007112A2 (zh)
CY (1) CY1124580T1 (zh)
DK (1) DK3389633T3 (zh)
EA (1) EA036513B1 (zh)
ES (1) ES2881883T3 (zh)
GB (1) GB2564262A (zh)
GE (1) GEP20207176B (zh)
HK (1) HK1254573A1 (zh)
HR (1) HRP20211590T1 (zh)
HU (1) HUE056269T2 (zh)
IL (1) IL260085B (zh)
LT (1) LT3389633T (zh)
MA (1) MA44079B1 (zh)
MX (1) MX2018007281A (zh)
PH (1) PH12018501292A1 (zh)
PL (1) PL3389633T3 (zh)
PT (1) PT3389633T (zh)
RS (1) RS62422B1 (zh)
SG (1) SG11201805142RA (zh)
SI (1) SI3389633T1 (zh)
UA (1) UA122592C2 (zh)
WO (1) WO2017103941A1 (zh)
ZA (1) ZA201804203B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
CZ2017821A3 (cs) * 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
EP3793527A1 (en) * 2018-05-14 2021-03-24 Capsugel Belgium NV Solid dosage forms with high active agent loading
JP7368548B2 (ja) * 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用
CN115583634B (zh) * 2022-09-21 2023-06-06 广东工业大学 一种碳氮聚合物材料的制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
MX2007002819A (es) 2004-09-09 2007-08-14 Natco Pharma Ltd Nuevos derivados de fenilaminopirimidina como inhibidores de bcl-abl cinasa.
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN102836159B (zh) * 2011-06-24 2014-12-10 南京圣和药业股份有限公司 达沙替尼分散体及其制备方法和其在片剂中的应用
WO2015095659A2 (en) * 2013-12-20 2015-06-25 Phosphorex, Inc. Indirubin solid dispersion composition

Also Published As

Publication number Publication date
GB201811142D0 (en) 2018-08-22
BR112018012458A2 (pt) 2018-12-18
MA44079B1 (fr) 2021-10-29
EP3389633A4 (en) 2019-08-07
EP3389633B1 (en) 2021-07-14
US10383872B2 (en) 2019-08-20
ES2881883T3 (es) 2021-11-30
EA201891443A1 (ru) 2019-01-31
DK3389633T3 (da) 2021-08-30
PT3389633T (pt) 2021-08-05
GEP20207176B (en) 2020-11-10
JP6896738B2 (ja) 2021-06-30
JP2021059551A (ja) 2021-04-15
UA122592C2 (uk) 2020-12-10
EP3389633A1 (en) 2018-10-24
CN108495620B (zh) 2021-09-03
CO2018007112A2 (es) 2018-07-19
SI3389633T1 (sl) 2021-11-30
PH12018501292A1 (en) 2019-02-04
GEAP201614833A (zh) 2020-06-25
AU2016373574B2 (en) 2021-10-14
CA3008634A1 (en) 2017-06-22
JP2018538325A (ja) 2018-12-27
IL260085A (en) 2018-07-31
PL3389633T3 (pl) 2021-12-13
MA44079A (fr) 2021-04-21
SG11201805142RA (en) 2018-07-30
WO2017103941A1 (en) 2017-06-22
ZA201804203B (en) 2020-08-26
RS62422B1 (sr) 2021-10-29
HUE056269T2 (hu) 2022-02-28
US20190015412A1 (en) 2019-01-17
MX2018007281A (es) 2018-11-29
HRP20211590T1 (hr) 2022-01-07
CN108495620A (zh) 2018-09-04
GB2564262A (en) 2019-01-09
KR20180102584A (ko) 2018-09-17
CY1124580T1 (el) 2022-07-22
LT3389633T (lt) 2021-09-10
IL260085B (en) 2021-09-30
CL2018001590A1 (es) 2018-11-30
EA036513B1 (ru) 2020-11-18
AU2016373574A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
HK1225655A1 (zh) 包含azd9291的藥用組合物
GB201419257D0 (en) Pharmaceutical compositions
GB201618482D0 (en) Pharmaceutical compositions
IL249553A0 (en) Pharmaceutical preparations
GB201608323D0 (en) Pharmaceutical compositions
IL271759A (en) Pharmaceutical preparations that include anthraxtinib
HK1254573A1 (zh) 包含苯基氨基嘧啶衍生物的藥物組合物
GB201521462D0 (en) Pharmaceutical composition
HK1245073A1 (zh) 藥物組合物
GB201515310D0 (en) Pharmaceutical composition
IL250817A0 (en) pharmaceutical preparations
GB201520862D0 (en) Pharmaceutical composition
IL263999A (en) Pharmaceutical compositions
PL3200772T3 (pl) Kompozycje farmaceutyczne zawierające alpelisyb
ZA201705782B (en) Pharmaceutical compositions
ZA201705783B (en) Pharmaceutical compositions
GB201700831D0 (en) Pharmaceutical compositions
PT3319596T (pt) Composições farmacêuticas
GB201520762D0 (en) Novel pharmaceutical compositions
GB201506598D0 (en) Pharmaceutical compositions
GB201521456D0 (en) Pharmaceutical composition
SG2014014872A (en) Pharmaceutical compositions
GB201408432D0 (en) Pharmaceutical compositions